The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Improving the OncotypeDX ordering process in patients with ER+ HER2- early-stage breast cancer: A longitudinal QI project.
 
Emily L. Podany
No Relationships to Disclose
 
Paula Goldberg
No Relationships to Disclose
 
Cynthia X. Ma
Consulting or Advisory Role - AstraZeneca; Biovica; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/Astra Zeneca; Danatlas; Genzyme; Gilead Sciences; Lilly; Merck; Novartis; Olaris; Pfizer; Regor Therapeutics Group; Stemline Therapeutics; Tempus; Tersera; Tersera
Research Funding - Pfizer (Inst); Puma Biotechnology (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate: Authorship - served as a co-author on the subject of endocrine therapy for metastatic breast cancer and receive compensation as an author, less than a few hundred dollars a year. It does not affect my patient care or research.
Travel, Accommodations, Expenses - SABCS; Total Health Conferencing
 
Andrew A. Davis
Consulting or Advisory Role - bioTheranostics; Pfizer